SCHEMBL3852226

SCHEMBL3852226

CC(C)(C)OC(=O)N1CCN(c2cccc3c2CC(=O)N3Cc2cccc(F)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.48
HTR6 P50406 1/20 0.47
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NPY2R P49146 1/20 0.42
IDO1 P14902 1/20 0.41
TDO2 P48775 1/20 0.41
IDO2 Q6ZQW0 1/20 0.41
MAPT P10636 1/20 0.41
TP53 P04637 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
GAA P10253 1/20 0.40
CCNT1 O60563 1/20 0.40
KDM1A O60341 2/20 0.40
ACHE P22303 1/20 0.39
HDAC1 Q13547 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853602 0.86 GPR119 (0.51) GPR119HTR6MAPTTP53CYP2D6
SCHEMBL4614431 0.86 GPR119 (0.48) GPR119HTR6KMT2AMEN1NPY2R
SCHEMBL27737587 0.86 KMT2A (0.44) HTR6KMT2AMEN1NPY2RMAPT
SCHEMBL3854930 0.83 GPR119 (0.48) GPR119KMT2AMEN1NPY2RIDO1
SCHEMBL3857354 0.82 GPR119 (0.49) GPR119HTR6KMT2ANPY2RIDO1
SCHEMBL3853259 0.82 GPR119 (0.47) GPR119KMT2AMEN1NPY2RIDO1
SCHEMBL3852196 0.81 GPR119 (0.47) GPR119KMT2AMEN1NPY2RIDO1
SCHEMBL13685808 0.79 GPR119 (0.47) GPR119TP53CCNT1ACHE
Tert-Butyl Formate SCHEMBL27737588 0.79 HTR6 (0.46) HTR6KMT2AMEN1MAPTTP53
SCHEMBL8536087 0.79 CYP2D6 (0.61) GPR119KMT2AMEN1NPY2RIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7582760-B2 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. ROCHE PALO ALTO LLC (US) 2009-09-01 US disclosed
US-7582760-B2 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. ROCHE PALO ALTO LLC (US) 2009-09-01 US disclosed
US-7582760-B2 7-Chloro-1-(3-fluoro-benzyl)-4-piperazin-1-yl-1,3-dihydro-benzoimidazol-2-one; useful for modulating the 5-HT6 receptor; useful in the treatment of certain CNS disorders such as Parkinson's disease, Huntington's disease, anxiety, depression, manic depression, psychoses, epilepsy etc. ROCHE PALO ALTO LLC (US) 2009-09-01 US disclosed
WO-2007006677-A1 BENZIMIDAZOLE DERIVATIVES AS 5-HT6,5-HT24 F. HOFFMANN-LA ROCHE AG (CH) 2007-01-18 WO disclosed
US-20070015744-A1 Benzimidazolone and dihydroindolone derivatives and uses thereof ROCHE PALO ALTO LLC 2007-01-18 US disclosed
US-20070015744-A1 Benzimidazolone and dihydroindolone derivatives and uses thereof ROCHE PALO ALTO LLC 2007-01-18 US disclosed
US-20070015744-A1 Benzimidazolone and dihydroindolone derivatives and uses thereof ROCHE PALO ALTO LLC 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015744-A1 Benzimidazolone and dihydroindolone derivatives and uses thereof RECQL, AR, DHX35 GPR119 1083/4885HTR6 1077/4885KMT2A 3038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.